Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio, Inc. is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics. Lead candidate KB103 is an investigational enzyme replacement therapy designed to address congenital hyperbilirubinemia by restoring deficient UGT1A1 activity. In parallel, Korro Bio is advancing a portfolio of live microbial drug candidates aimed at modulating the human microbiome to treat unmet medical needs in gastroenterology and oncology. These programs reflect the company’s dual focus on systemic enzyme therapies and targeted microbial approaches.

Founded in 2019 and headquartered in Boston, Massachusetts, Korro Bio completed its initial public offering on the Nasdaq under the ticker KRRO in late 2021. The company collaborates with leading academic and industry partners to expand its enzyme discovery platform and accelerate translational research. Led by an experienced management team with backgrounds in biotherapeutics, protein science and drug development, Korro Bio serves a global pharmaceutical customer base and is committed to advancing innovative treatments from bench to bedside.

Key Stats

• Today's Range: $11.53 to $12.30
• 50-Day Range: $10.07 to $14.72
• 52-Week Range: $5.20 to $55.89
• Volume: 78,429 shs
• Average Volume: 77,060 shs
• Market Capitalization: $180.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.71
• Consensus Rating: Moderate Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 51% of companies evaluated by MarketBeat, and ranked 468th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Korro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Korro Bio has a consensus price target of $16.71, representing about 36.6% upside from its current price of $12.24.

Amount of Analyst Coverage

Korro Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Korro Bio are expected to grow in the coming year, from ($4.97) to ($4.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.78% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 14.28, which indicates bearish sentiment.

Change versus previous month

Short interest in Korro Bio has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.73

News Sentiment

Korro Bio has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Korro Bio this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for KRRO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have sold 5,616.83% more of their company's stock than they have bought. Specifically, they have bought $78,815.00 in company stock and sold $4,505,723.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

13.18% of the stock of Korro Bio is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.frequencytx.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 70
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Korro Bio: $16.71
• High Price Target: $23.00
• Low Price Target: $10.00
• Potential Upside/Downside: +36.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.26 million
• Net Margins: -1,834.48%
• Pretax Margin: -4,441.85%
• Return on Equity: -114.26%
• Return on Assets: -68.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.55
• Quick Ratio: 9.55

Sales & Book Value

• Annual Sales: $6.39 million
• Price / Sales: 28.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.46 per share
• Price / Book: 2.24

Miscellaneous

• Outstanding Shares: 14,730,000
• Free Float: 14,019,000
• Market Cap: $180.30 million
• Optionable: No Data
• Beta: 3.09